Thoma Bravo related stories
All articles and analysis
How PE learned to stop worrying and love inflationThe current debate about whether the inflation spike we are seeing is ‘transitory’ should be reframed as ‘reflation vs sustained inflation’, according to Commonfund’s Ryan Driscoll.
Side Letter: Europe's newest alts giant; PEI 300; JPMAM taps CPP vetToday's the day! This year's PEI 300 ranking is live. Plus: Europe's newest alts giant and a CPP Investments veteran has moved to JPMorgan Asset Management. Here's today's brief, for our valued subscribers only.
KKR, CD&R buy Cloudera for ~$5.3b, RiverGlade, Thurston, prep oral surgery platform for sale, New Mountains' DRB Systems starts auctionKKR and CD&R take Cloudera private for about $5.3 billion and U.S. Oral Surgery Management goes on the block.
New Mountain starts DRB Systems sale processDRB, vertical software provider for a niche segment in the automotive vertical, is likely to see a mix of strategics and PE firms bidding in the auction's first round, sources tell PE Hub.
PEI 300 2021: Buy high, sell higher – the mid-market rolls onRising multiples have not weakened enthusiasm for a segment that has historically outperformed the rest.
PEI 300 2021: Growth equity offers best of both worldsA lot of capital is swirling around growth equity, a sign of the strategy’s growing appeal beyond buyouts and venture capital.
PEI 300 2021: Immune response to covidWhat pandemic? The industry’s 300 largest firms raised a record $2.25 trillion in fresh capital over the past five years.
PEI 300 2021: Tech cements its place at the topTechnology specialists are hot on the heels of the very largest multi-asset managers with the pandemic adding further impetus.
Big exits: MidOcean makes 8.5x on The Planet Group, Riverside's Greenphire goes for ~$1.1bMidOcean generates handsome return on The Planet Group, Riverside exits Greenphire for ~$1.1b as Thoma bets on future of clinical research
Thoma Bravo values Greenphire at ~$1.1bn as tech transforms clinical researchAlready proving a home run investment for Riverside, Greenphire remains on a fast growth track as the clinical research market remains largely dominated by manual, paper-based workflows.